Form 4: Intellia CEO Sells Shares After Option Exercise

Intellia Therapeutics' President and CEO, John M. Leonard, sold a significant number of shares following the exercise of stock options under a pre-arranged 10b5-1 trading plan.

Summary

• John M. Leonard, President and CEO, and Director of Intellia Therapeutics, Inc. (NTLA), reported transactions involving the company's common stock.
• On December 11, 2025, Mr. Leonard acquired 49,959 shares of common stock by exercising stock options at a price of $6.83 per share.
• Immediately following the option exercise on December 11, 2025, he sold a total of 88,146 shares of common stock in three separate transactions at weighted average prices of $9.49, $9.47, and $9.59 per share.
• These sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted on September 11, 2025.
• On December 12, 2025, Mr. Leonard acquired an additional 8,557 shares of common stock by exercising stock options at a price of $6.83 per share.
• The stock options exercised had vested in full as of December 11, 2025, and were issued under the Intellia Therapeutics, Inc. Amended and Restated 2015 Stock Option and Incentive Plan.
• Following these transactions, Mr. Leonard directly beneficially owns 1,047,485 shares of common stock and indirectly owns 58,415 shares through the John M. Leonard 2015 Irrevocable Trust.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan, which is a common practice for executives for diversification or liquidity and does not inherently signal strong positive or negative sentiment about the company's future.

Positives

• The exercise of stock options indicates that the insider saw value in acquiring shares at the exercise price of $6.83.
• The shares were sold at prices significantly higher than the exercise price, ranging from $9.30 to $9.65, indicating a profitable transaction for the insider.

Negatives

• The sale of a substantial number of shares by a key executive, even if pre-planned, can sometimes be perceived as a lack of confidence, although this is often for diversification or liquidity purposes.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• The sales reported occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on September 11, 2025.

Industry Context

This filing is a routine insider transaction report specific to Intellia Therapeutics and its executive, John M. Leonard. It does not provide information directly related to broader industry trends or competitive landscape.

Corporate Governance

Related Party Transactions

• 58,415 shares are held indirectly by the John M. Leonard 2015 Irrevocable Trust.

Stakeholder Impact

• Shareholders: The sale of shares by a CEO, even under a 10b5-1 plan, slightly increases the float and could be viewed with minor concern by some, though it's a common practice for executive compensation and diversification.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing details routine insider transactions involving the exercise of stock options and subsequent sale of shares under a pre-arranged 10b5-1 trading plan. Such transactions are common for executives for diversification or liquidity purposes and do not typically indicate a change in the company's fundamental outlook. Therefore, a 'hold' recommendation is appropriate as this filing alone does not provide new information to alter an existing investment thesis.

Keywords

Intellia Therapeutics, NTLA, Form 4, insider trading, stock options, CEO, share sale, 10b5-1 plan, beneficial ownership, executive compensation